Hemostemix Inc. (CVE:HEM – Get Free Report) dropped 5.6% during trading on Tuesday . The stock traded as low as C$0.09 and last traded at C$0.09. Approximately 74,700 shares were traded during trading, an increase of 6% from the average daily volume of 70,178 shares. The stock had previously closed at C$0.09.
Hemostemix Price Performance
The company has a market cap of C$7.84 million, a PE ratio of -4.50 and a beta of 0.15. The stock’s 50-day moving average is C$0.05 and its 200 day moving average is C$0.05.
About Hemostemix
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions. The company develops cell therapy products from the patient's own blood, which is a non-invasive source of therapeutic cells. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia in Canada and the United States.
Featured Stories
- Five stocks we like better than Hemostemix
- Most active stocks: Dollar volume vs share volume
- Galmed Pharmaceuticals Surges 400%: What’s Behind the Explosion?
- Basic Materials Stocks Investing
- Gold Hits New All-Time Highs: 3 Stocks to Ride the Surge
- What Investors Need to Know to Beat the Market
- Intel: Why It’s Time to Reconsider This Beaten-Down Chipmaker
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
